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Abstract Taxanes are a standard first-line option for
metastatic breast cancer (MBC), but their utility may be
limited by primary or acquired resistance. New microtu-
bule-targeting agents have been developed to overcome
taxane resistance and provide additional options for
improving patient outcomes. This article reviews these
alternative microtubule-targeting agents and their potential
clinical benefits for MBC patients. Relevant clinical data
were compiled through searches within PubMed and con-
gress abstract databases. Ixabepilone, a novel microtubule-
stabilizing drug approved by the US Food and Drug
Administration (FDA), has proven efficacy across multiple
lines of therapy, including patients with taxane-resistant/
refractory disease. In phase III trials, ixabepilone plus
capecitabine significantly improved progression-free sur-
vival compared with capecitabine alone in anthracycline/
taxane-pretreated patients. Eribulin has recently been
approved by the FDA and by the European Medicines
Agency for the treatment of patients with MBC who have
received at least two prior chemotherapy regimens for late-
stage disease. In a phase III trial, eribulin extended overall
survival compared with the physician’s treatment choice in
heavily pretreated MBC patients. In addition, several
investigational microtubule-targeting agents may have
therapeutic potential in MBC. The development of new
microtubule-targeting agents helps to address the need for
additional effective regimens for patients progressing after
standard treatment with anthracycline- and taxane-con-
taining regimens.
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Introduction
Recurrent or metastatic breast cancer (MBC) continues to
be an incurable disease with a poor prognosis and a median
5-year survival of only 23–26% [1, 2]. Effective long-term
management of MBC poses significant clinical challenges.
Modern chemotherapeutic approaches aim to improve
survival duration and palliate symptoms while minimizing
toxicity and maintaining quality of life [3]. Taxanes, such
as paclitaxel and docetaxel, are a cornerstone of treatment
across multiple lines of therapy. However, the clinical
usefulness of these microtubule inhibitors is often con-
strained by primary or acquired resistance, the latter fre-
quently resulting from taxane use in the adjuvant or
neoadjuvant setting [4, 5]. Resistance underscores the need
for additional treatment options for women progressing on
standard chemotherapy. Reviewed in this article are several
novel antineoplastic drugs targeting microtubules that have
provided new treatment options for patients with MBC
resistant to taxane therapy. Relevant clinical data were
compiled through searches within PubMed and congress
abstract databases with no date limits, specific inclusion, or
exclusion criteria applied.
Treatment approach and role of taxanes in MBC
The selection of treatment for MBC is strongly influenced
by the estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2)
status of the tumor [3, 6]. Systemic chemotherapy is
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appropriate for women whose disease is refractory to
endocrine therapy, hormone receptor-negative, or rapidly
progressive with visceral involvement [3, 6]. In this setting,
combination chemotherapy is associated with a rapid
response but greater toxicity and similar survival outcomes
compared with the sequential use of single cytotoxic drugs
[3, 6]. For women with HER2-positive disease, trast-
uzumab-based therapy is the standard of care, and lapatinib
plus capecitabine is a reasonable option in trastuzumab-
refractory disease [3, 6]. The antiangiogenic drug bev-
acizumab improved progression-free survival (PFS) when
added to weekly paclitaxel, 3-weekly docetaxel, and
capecitabine in first-line treatment of MBC [7–9]. Overall
survival (OS) was not prolonged compared with chemo-
therapy alone but OS is difficult to observe in setting with a
long post-progression survival such as first-line HER2-
negative MBC [10].
Taxane resistance
The increased use of taxanes in early-stage breast cancer
has lead to higher rates of resistance to these drugs by the
time of disease recurrence, thereby reducing their effec-
tiveness and usefulness in the treatment of MBC. Even
among taxane-naı¨ve patients, primary resistance to taxanes
is a critical factor for disease progression. Taxane resis-
tance rates of up to 55% have been reported in anthracy-
cline-pretreated patients and up to one-third of
anthracycline-naı¨ve patients [4].
Taxanes bind reversibly to b-tubulin, which stabilizes
microtubule complexes and promotes microtubule poly-
merization leading to cell-cycle arrest and apoptosis [11].
Resistance to taxanes can develop via a number of different
mechanisms. The overexpression of P-glycoprotein and
other ATP-binding cassette transport proteins promotes
drug efflux from the tumor cell, which effectively reduces
drug concentrations at target sites. P-glycoprotein, encoded
by the MDR-1 gene, confers resistance to both taxanes and
anthracyclines [12]. Taxane resistance can also develop
from b-tubulin gene mutations, overexpression of bIII-
tubulin or microtubule-associated proteins, and alterations
in mitotic checkpoint signaling proteins [13].
The bIII-tubulin isotype has a different amino acid
sequence and post-translational modifications compared
with other b-tubulin isotypes, which leads to reduced pac-
litaxel binding [14–16]. The overexpression of bIII-tubulin
has been associated with clinical resistance to taxanes in
several studies. For example, high versus low bIII-tubulin
expression was predictive of progression on paclitaxel-
based chemotherapy in a cohort of 70 patients with
advanced breast cancer [17]. Similarly, bIII-tubulin over-
expression was associated with a significantly higher rate of
disease progression in a cohort of 92 advanced breast cancer
patients receiving first-line paclitaxel-based chemotherapy
(35 vs. 7%, P \ 0.002) [18]. The development of new
taxanes and new taxane formulations has not resolved the
problem of primary and acquired resistance, which has
driven the search for alternative agents that could be used in
taxane-resistant disease or replace taxanes in early stages of
treatment. A number of novel agents targeting microtubules
have been recently developed for use in breast cancer.
Epothilones: novel microtubule-targeting agents
for MBC
The epothilones—identified initially from the myxobacte-
rium Sorangium cellulosum [19]—are a novel class of
microtubule-stabilizing drugs [20] that have low suscepti-
bility to common mechanisms conferring resistance to
taxanes and other cytotoxic agents, including P-glycopro-
tein overexpression [21]. Moreover, unlike the taxanes, the
epothilones bind effectively to bIII-tubulin [16] and con-
sequently retain activity in taxane-resistant tumors over-
expressing bIII-tubulin [22, 23]. Ixabepilone is the only
epothilone approved by the US Food and Drug Adminis-
tration (FDA). Preclinical studies showed that ixabepilone,
a semi-synthetic derivative of natural epothilone B, is
active in taxane-sensitive and -resistant tumor cell lines and
tumor xenografts [23, 24]. Preclinical studies also showed
synergistic antitumor activity between ixabepilone and
other anticancer drugs, including capecitabine [25, 26].
Clinical activity of ixabepilone in MBC
Ixabepilone is approved for use in locally advanced or
MBC, either as monotherapy following progression on an
anthracycline, a taxane, and capecitabine, or in combina-
tion with capecitabine following failure of an anthracycline
and a taxane. It may be used in early therapy lines of MBC
resistant to these other drugs. Ixabepilone (40 mg/m2 once
every 3 weeks), either alone or in combination with
capecitabine 2,000 mg/m2/day on days 1–14, was effective
with acceptable toxicity in clinical trials in MBC patients
including those resistant to taxanes or heavily pretreated
(Table 1) [27–31]. In phase II trials, objective response
rates to ixabepilone monotherapy ranged from 11.5% in
patients with MBC resistant to anthracyclines, taxanes, and
capecitabine [27] to 57% in MBC patients previously
untreated with taxanes [36]. Median survival of patients
with taxane-resistant or anthracycline-, taxane-, and cape-
citabine-resistant disease treated with ixabepilone was 7.9
and 8.6 months, respectively [27, 28].
Combination therapy with ixabepilone plus capecitabine
was superior to capecitabine alone after failure of anthra-
cycline and taxane treatment in two large, randomized
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phase III studies (Table 2) [4, 32–34]. The pivotal trial
included 752 patients with advanced or MBC previously
treated or resistant to anthracyclines and resistant to tax-
anes [32]. Ixabepilone plus capecitabine significantly pro-
longed median PFS relative to capecitabine monotherapy
(5.8 vs. 4.2 months; P = 0.0003) and reduced risk of dis-
ease progression by 25% [32]. Objective responses were
more common with the combination than with capecitabine
alone in overall population (35 vs. 14%; P \ 0.0001) [32]
and in patients with primary taxane resistance (33 vs. 13%;
P \ 0.0001) [4]. Median OS was not significantly longer in
the combination therapy group (12.9 vs. 11.1 months;
P = 0.19) [33].
Ixabepilone plus capecitabine was also evaluated in a
larger phase III trial that enrolled 1,221 MBC patients
previously treated with, but not necessarily resistant to,
anthracyclines and taxanes [34]. Overall, 74% of the study
cohort was not resistant to anthracyclines and 52% were not
resistant to taxanes. The combination regimen significantly
improved median PFS (6.2 vs. 4.2 months; P = 0.0005)
and response rate (43 vs. 29%; P \ 0.0001) compared with
single-agent capecitabine [34]. Despite the PFS benefit, a
significant improvement in OS was not observed (16.4 vs.
15.6 months; P = 0.116). Pooled analyses of the phase III
clinical trials demonstrated that ixabepilone offers clinical
benefits across a broad range of patients with advanced or
MBC and within specific patient subsets, including taxane-
resistant disease, relapse within 1 year of anthracycline/
taxane therapy, triple-negative breast cancer, symptomatic
with a poor prognosis, and heavy visceral disease burdens to
the liver and lung [4, 35–39].
The most common ixabepilone-related adverse event
was peripheral neuropathy, which was primarily sensory
and generally reversible with dose reduction or delay. In
the two phase III trials, the incidence of peripheral neu-
ropathy in the ixabepilone plus capecitabine arms was 67
and 66%, respectively (including 22–24% grade 3 and
\1% grade 4) [32, 34].
Other ixabepilone-based combinations
Ixabepilone has also been evaluated in combination with
other agents. In the phase II Eastern Cooperative Oncology
Group E2103 trial, ixabepilone was administered at a dose
of 15 mg/m2 in combination with trastuzumab and carbo-
platin area under curve 2 on days 1, 8, and 15 of a 4 week
cycle to 59 patients with HER2-positive MBC as first-line
therapy [40]. Trastuzumab was administered weekly (4 mg/
kg initially, then 2 mg/kg) during chemotherapy, and then
every 3 weeks (6 mg/kg) until disease progression.
Table 2 Efficacy of ixabepilone in combination with capecitabine in patients with MBC in phase III trials
Ixabepilone ? capecitabinea Capecitabine monotherapyb HR (95% CI) P value
Trial 046 (Yardley et al. [4]; Thomas et al. [32]; Hortobagyi et al. [33])
Overall populationc n = 375 n = 377
ORRd, % (95% CI) 34.7 (30–40) 14.3 (10.9–18.3) – \0.0001
Median PFSd, months (95% CI) 5.8 (5.5–7.0) 4.2 (3.8–4.5) 0.75 (0.64–0.88) 0.0003
Median OS, months (95% CI) 12.9 (11.5–14.2) 11.1 (10.0–12.5) 0.90 (0.77–1.05) 0.1936
Subset with primary taxane resistancee N = 150 N = 137
ORR, % (95% CI) 33 (25.9–41.5) 13 (8.0–20.0) – \0.0001
Median PFS, months (95% CI) 5.6 (4.3–7.0) 4.9 (4.0–5.7) 0.83 –
Trial 048 (Hortobagyi et al. [33], Sparano et al. [34])
Overall populationf n = 609 n = 612
ORR, % (95% CI) 43.3 (38.7–47.9) 28.8 (24.7–33.2) – \0.0001
Median PFS, months (95% CI) 6.2 (5.6–6.8) 4.4 (4.1–5.4) 0.79 (0.69–0.90) 0.0005
Median OS, months 16.4 (14.9–17.9) 15.6 (13.9–17.0) 0.90 (0.78–1.03) 0.1162
a Ixabepilone 40 mg/m2 i.v. on day 1 plus oral capecitabine 1,000 mg/m2 twice daily on days 1–14 of a 3 week cycle
b Capecitabine 1,250 mg/m2 PO twice daily on days 1–14 of a 3 week cycle
c Patients with locally advanced or MBC previously treated with or resistant to anthracyclines and resistant to taxanes. Resistance was defined by
tumor progression during treatment or within 3 months of the last dose for MBC, or recurrence within 6 months of treatment in the adjuvant or
neoadjuvant settings
d As determined by independent radiology review
e Primary resistance defined by progressive disease as best response in previous therapy
f Patients with locally advanced or MBC treated previously with an anthracycline and a taxane
ORR objective response rate
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Objective responses were achieved in 26 patients (44%); the
median time to progression was 8.2 months and median OS
was 34.7 months. The regimen had an acceptable tolera-
bility profile and efficacy was assessed by investigators as
comparable with that achieved with paclitaxel, carboplatin,
and trastuzumab.
The feasibility of administering ixabepilone with an
anthracycline was shown in two phase I trials. Ixabepilone
plus pegylated liposomal doxorubicin (PLD) yielded
objective responses in three of 13 patients (23%) with
taxane-pretreated advanced breast cancer [41]. The rec-
ommended regimen for further evaluation was ixabepilone
16 mg/m2 on days 1, 8, and 15 plus PLD 30 mg/m2 on day
1 of a 4 week cycle. Preliminary data from a phase Ib trial
indicated that ixabepilone plus epirubicin has favorable
efficacy in patients with advanced breast cancer who had a
progression-free interval of C3 months following adjuvant
anthracyclines [42]. Partial responses were seen in 10 of 12
women with measurable disease. The suggested dose for
further evaluation was ixabepilone 30 mg/m2 plus epiru-
bicin 75 mg/m2 every 3 weeks.
Finally, ixabepilone plus bevacizumab was compared
with paclitaxel plus bevacizumab as first-line therapy for
HER2-negative MBC in a randomized phase II trial [43]. A
total of 123 women were allocated to one of three treat-
ment arms: ixabepilone 16 mg/m2 on days 1, 8, and 15
every 4 weeks plus bevacizumab 10 mg/kg every 2 weeks;
ixabepilone 40 mg/m2 and bevacizumab 15 mg/kg every
3 weeks; or paclitaxel 90 mg/m2 plus bevacizumab
according to the schedule in the first arm. The three-week
regimen of ixabepilone/bevacizumab had similar efficacy
to the paclitaxel/bevacizumab regimen; the weekly ixab-
epilone regimen was somewhat less effective but better
tolerated.
Other epothilones
Other epothilones are currently in clinical development,
including epothilone B (patupilone) and the epothilone B
derivative sagopilone. To date, only limited data are
available with these agents in breast cancer although
activity has been shown across a range of solid tumor types
including taxane-resistant tumors [44]. Patupilone (10 mg/
m2 every 3 weeks) is being evaluated in a phase II trial in
MBC patients with brain metastases that progressed or
recurred after whole brain radiation therapy; preliminary
results indicated a partial response in one of the first 17
patients (6%) [45]. Three-month PFS in the central nervous
system was 8%, and grade 3/4 toxicities were mostly
gastrointestinal events. The tolerability profile of patupi-
lone may differ from that of ixabepilone, presumably
because of differences in tissue distribution and metabo-
lism [44].
Sagopilone is being investigated in a broad clinical
program that includes breast cancer. In a phase II trial of 65
women with MBC who had previously received an
anthracycline and a taxane, sagopilone 16 or 22 mg/m2
every 3 weeks produced three confirmed responses (5%)
[46]; sensory neuropathy and fatigue were the main treat-
ment-related adverse events, occurring in 82 and 45% of
patients, respectively. The investigators of this study con-
cluded that sagopilone has limited activity in heavily pre-
treated MBC patients.
Other novel microtubule-targeting agents
Eribulin was recently approved by the FDA and the
European Medicines Agency (EMA) for the treatment of
patients with MBC who have received at least two prior
chemotherapy regimens for late-stage disease. Several
other novel non-taxane, non-epothilone, microtubule-tar-
geting drugs are under early stages of clinical development.
Eribulin
Eribulin, a synthetic analog of the marine macrolide hali-
chondrin B, is a microtubule inhibitor with a unique
mechanism of action. Eribulin inhibits microtubule stability
by blocking microtubule growth without affecting micro-
tubule shortening, thereby sequestering b-tubulin into non-
functional aggregates and leading to formation of abnormal
mitotic spindles and ultimately apoptosis [47, 48]. Phases I
and II studies indicated that eribulin has activity with
acceptable toxicity in MBC, including patients pretreated
with anthracyclines and taxanes. Eribulin (1.4 mg/m2) was
initially administered on days 1, 8, and 15 of a 4-week cycle
but caused significant neutropenia on day 15 [49], and was
subsequently evaluated using dosing on days 1 and 8 of a
3-week cycle. Phase II trials were conducted in MBC
patients who had received a median of four previous che-
motherapy regimens; the first enrolled anthracycline and
taxane-pretreated patients, and the second enrolled patients
previously treated with anthracyclines, taxanes, and cape-
citabine (Table 3) [49, 50]. Eribulin produced objective
responses in 11.5 and 9.3% of patients in the first and sec-
ond trial, respectively, and clinical benefit (which includes
stable disease C6 months) in 17% of patients in both studies
[49, 50]. Median OS was 9.0 months in the first trial and
10.4 months in the second trial.
On the basis of the phase II results, two open-label, ran-
domized, phase III trials evaluated eribulin monotherapy [52].
The first trial (EMBRACE) compared eribulin versus the
physician’s choice of treatment in 762 patients with anthra-
cycline and taxane-pretreated locally recurrent or MBC [51].
Patients were required to have received two to five previous
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chemotherapy regimens, including at least two regimens for
recurrent or MBC; 73% had previously received capecitabine.
The physician’s choice included any monotherapy, and no
patients received supportive care alone. In total, 96% received
chemotherapy, most commonly vinorelbine, gemcitabine, or
capecitabine. Eribulin significantly improved median OS
compared with the physician’s treatment choice (13.1 vs.
10.6 months; P = 0.041; Table 3). On independent review,
eribulin also produced a higher response rate (12 vs. 5%;
P = 0.002) and showed a trend for improving PFS (3.7 vs.
2.2 months; P = 0.137). Eribulin had a manageable tolera-
bility profile, with grade 3/4 neutropenia in 45% of patients.
Notably, EMBRACE is the first phase III study to show a
survival benefit for single-agent therapy in heavily pretreated
MBC patients. The other phase III trial is comparing eribulin
versus capecitabine in 1,102 locally advanced or MBC
patients who had received up to three prior chemotherapy
regimens including an anthracycline and a taxane, but no more
than two regimens for advanced or MBC [52].
Ispinesib
The kinesin spindle protein plays an essential role in
spindle formation during mitosis; its inhibition leads to
mitotic arrest, formation of characteristic monoaster spin-
dles, and ultimately apoptosis [53]. Ispinesib is a potent
and selective small molecule inhibitor of the kinesin
spindle protein. In preclinical evaluations, ispinesib had
broad antiproliferative activity against a panel of breast
cancer cell lines and induced tumor regression in breast
cancer xenografts [54]. In these latter models, ispinesib
enhanced the antitumor activity of trastuzumab, lapatinib,
doxorubicin, and capecitabine. In a phase II trial, ispinesib
produced a response rate of 9% in patients with locally
advanced or MBC who had relapsed after prior treatment
with an anthracycline and a taxane, and exhibited a rela-
tively low neurotoxicity, gastrointestinal toxicity, and hair
loss [55]. When administered on days 1, 8, and 15 of a
4-week cycle, the maximum tolerated dose (MTD) in
patients with advanced solid tumors was 7 mg/m2 and
neutropenia was the dose-limiting toxicity [56]. Stable
disease was the best response in 9 of 30 patients. Several
phase I trials have evaluated ispinesib in combination with
docetaxel, carboplatin, or capecitabine in patients with
advanced solid tumors, and identified a MTD [57–59].
According to ClinicalTrials.gov, there are no active trials
ongoing with ispinesib in breast cancer.
Vinflunine
Vinflunine is a semi-synthetic fluorinated vinca alkaloid
that suppresses microtubule dynamics and treadmilling,
and blocks microtubule assembly, which leads to cell-cycle
arrest, accumulation of cells in mitosis, and apoptosis [60].
Preclinical data suggest that vinflunine has potential for
treatment of a wide range of solid tumors, including breast
cancer with greater antitumor activity than vinorelbine
[60]. However, vinflunine is sensitive to P-glycoprotein-
mediated resistance like other vinca alkaloids although it
appears less likely to induce resistance than vinorelbine
[60]. Vinflunine 320 mg/m2 every 3 weeks was active with
predictable and manageable toxicity when administered to
MBC patients after prior anthracycline and taxane therapy,
producing response rates of 30 and 12.5% when used in
second-line and third-line therapy, respectively [61, 62].
Median PFS was 3.7 and 2.6 months, respectively, and
median OS was 14.3 and 11.4 months, respectively. The
most common grade 3/4 adverse events in these phase II
trials were neutropenia (65–70%), fatigue (14–17%), and
constipation (7–12%). In another phase II trial, vinflunine
plus trastuzumab produced responses in 33%, clinical
benefit in 71%, and PFS of 6.2 months in first-line therapy
of MBC, but no advantages compared with taxane/trast-
uzumab or vinorelbine/trastuzumab in this setting [63].
Vinflunine is currently undergoing phase III evaluation in
combination with capecitabine versus capecitabine alone in
MBC previously treated with an anthracycline and a tax-
ane, and as monotherapy versus the physician’s choice of
an alkylating agent in heavily pretreated MBC.
Other agents
Two other microtubule inhibitors are currently being
evaluated in phase II trials for MBC. Tesetaxel (DJ-927) is
an orally bioavailable docetaxel analog with greater anti-
tumor activity than paclitaxel or docetaxel against a wide
range of tumor cell lines and tumor xenografts [64].
Importantly, this agent remains active in tumor cells
expressing P-glycoprotein. It is currently being evaluated
as first-line therapy at a dose of 50 mg every 3 weeks.
Indibulin (D-24851) is an orally active agent that desta-
bilizes microtubules. Unlike the vinca alkaloids, indibulin
can distinguish between highly modified b-tubulin found in
mature neuronal microtubules and less-modified tubulin in
non-neuronal microtubules, thereby offering the potential
for reduced risk of neuropathy [65]. Indibulin has activity
against a wide range of tumor cell lines, including cells
resistant to taxanes, vinca alkaloids, and anthracyclines [66]
and is under evaluation in a phase I/II trial in MBC.
Individualizing MBC therapy beyond taxanes
The most appropriate use of non-taxane microtubule-tar-
geting agents in clinical practice remains to be defined.
Clearly, use of these agents in taxane-naı¨ve patients will
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require clinical evidence of equivalent efficacy compared
with the standard-of-care taxanes, and their use following
taxane failure will require continued evidence of clinical
benefit. Patient/clinical characteristics, treatment history,
and patient preference are important factors for non-taxane
therapy in MBC. Key patient/clinical characteristics
include tumor type (e.g., triple-negative breast cancer,
HER2-positive disease), the presence of visceral disease,
prognosis, and performance status. Ixabepilone appears to
be a useful treatment option for patients with these diffi-
cult-to-treat attributes. Treatment history includes the use
of taxanes and non-taxanes, number of previous regimens,
previous single versus combination therapy, and avail-
ability of alternative options. Eribulin or ixabepilone plus
capecitabine are effective options after previous taxane and
anthracycline failure, and single-agent ixabepilone is an
option once capecitabine has been used.
Conclusions
Taxanes are likely to remain a standard first-choice treat-
ment for MBC in the near future. However, drug resistance
often compromises the clinical benefits of taxanes, partic-
ularly in patients exposed to multiple lines of therapy. The
use of other microtubule-targeting agents, such as ixab-
epilone or eribulin may bring clinical benefit to patients
with taxane-resistant MBC who otherwise have very few
therapeutic options. Ixabepilone has low susceptibility to
most mechanisms conferring taxane resistance and has
activity in patients across multiple lines of therapy in the
advanced/metastatic disease setting. The recent approval of
eribulin after second-line MBC treatment expands the
treatment options available for patients with late-stage
disease. In addition, several emerging novel microtubule-
targeting agents appear to have therapeutic potential in
MBC. Ixabepilone with or without capecitabine is a viable
option for use in first-line or second-line therapy depending
on whether taxanes had been used in the neoadjuvant or
adjuvant settings, and eribulin is a promising option for use
after second-line therapy. The development of these
microtubule inhibitors helps to address the need for addi-
tional effective regimens for patients progressing after
standard treatment with anthracycline- and taxane-con-
taining regimens.
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